Longitudinal evolution of compensatory changes in striatal dopamine processing in Parkinson's disease
The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Parkinson's disease is a relentlessly progressive neurodegenerative disease. Breakdown of compensatory mechanisms influencing putaminal dopamine processing could contribute to the progressive motor symptoms. We studied a cohort of 78 subjects (at baseline) with sporadic Parkinson's disease and 35 healthy controls with multi-tracer positron emission tomography scans to investigate the evolution of adaptive mechanisms influencing striatal dopamine processing in Parkinson's disease progression. Presynaptic dopaminergic integrity was assessed with three radioligands: (i) [(11)C](±)dihydrotetrabenazine, to estimate the density of vesicular monoamine transporter type 2; (ii) [(11)C]d-threo-methylphenidate, to label the dopamine transporter; and (iii) 6-[(18)F]fluoro-L-DOPA, to assess the activity of aromatic amino acid decarboxylase and storage of 6-[(18)F]-fluorodopamine in synaptic vesicles. The subjects with Parkinson's disease and the healthy controls underwent positron emission tomography scans at the initial visit and after 4 and 8 years of follow-up. Non-linear multivariate regression analyses with random effects were utilized to model the longitudinal changes in tracer values in the putamen standardized relative to normal controls. We found evidence for possible upregulation of dopamine synthesis and downregulation of dopamine transporter in the more severely affected putamen in the early stage of Parkinson's disease. The standardized 6-[(18)F]fluoro-L-DOPA and [(11)C]d-threo-methylphenidate values tended to approach [(11)C](±)dihydrotetrabenazine values in the putamen in later stages of disease (i.e. for [(11)C](±)dihydrotetrabenazine values <25% of normal), when the rates of decline in the positron emission tomography measurements were similar for all the markers. Our data suggest that compensatory mechanisms decline as Parkinson's disease progresses. This breakdown of compensatory strategies in the putamen could contribute to the progression of motor symptoms in advanced disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Random-Effects Models for Longitudinal Data
Laird, N. M., & Ware, J. H. (1982) · Biometrics · doi:10.2307/2529876 · Cited by 8,923
Graphical Evaluation of Blood-to-Brain Transfer Constants from Multiple-Time Uptake Data
Patlak, C. S., Blasberg, R. G., & Fenstermacher, J. D. (1983) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.1983.1 · Cited by 3,567
AGEING AND PARKINSON'S DISEASE: SUBSTANTIA NIGRA REGIONAL SELECTIVITY
FEARNLEY, J. M., & LEES, A. J. (1991) · Brain · doi:10.1093/brain/114.5.2283 · Cited by 3,529
Uneven Pattern of Dopamine Loss in the Striatum of Patients with Idiopathic Parkinson's Disease
Kish, S. J., Shannak, K., & Hornykiewicz, O. (1988) · New England Journal of Medicine · doi:10.1056/nejm198804073181402 · Cited by 1,953
Patlak, C. S., & Blasberg, R. G. (1985) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.1985.87 · Cited by 1,673
Distribution Volume Ratios without Blood Sampling from Graphical Analysis of PET Data
Logan, J., Fowler, J. S., Volkow, N. D., Wang, G.-J., Ding, Y.-S., & Alexoff, D. L. (1996) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-199609000-00008 · Cited by 1,514 · cited 1×
“were calculated by Logan graphical method with reference tissue input function (Logan et al., 1996).”
MethodClinical progression in Parkinson disease and the neurobiology of axons
Cheng, H., Ulane, C. M., & Burke, R. E. (2010) · Annals of Neurology · doi:10.1002/ana.21995 · Cited by 1,012
Murphy, D. D., Rueter, S. M., Trojanowski, J. Q., & Lee, V. M.-Y. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-09-03214.2000 · Cited by 836
Criteria for diagnosing Parkinson's disease
Calne, D. B., Snow, B. J., & Lee, C. (1992) · Annals of Neurology · doi:10.1002/ana.410320721 · Cited by 628 · cited 1×
“(2009), who satisfied the clinical criteria for definite Parkinson’s disease (Calne et al., 1992) participated in the study (Table 1).”
BackgroundA Role for α-Synuclein in the Regulation of Dopamine Biosynthesis
Perez, R. G., Waymire, J. C., Lin, E., Liu, J. J., Guo, F., & Zigmond, M. J. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-08-03090.2002 · Cited by 598
Lee, C. S., Samii, A., Sossi, V., Ruth, T. J., Schulzer, M., Holden, J. E., Wudel, J., Pal, P. K., De La Fuente-Fernandez, R., Calne, D. B., et al. (2000) · Annals of Neurology · doi:10.1002/1531-8249(200004)47:4<493::aid-ana13>3.0.co;2-4 · Cited by 580 · cited 5×
“The scanning protocol and procedure, data processing and reconstruction are described in detail elsewhere (Lee et al., 2000).”
BackgroundMethodInfluentialSelf-citationBiochemical aspects of Parkinson's disease
Hornykiewicz, O. (1998) · Neurology · doi:10.1212/wnl.51.2_suppl_2.s2 · Cited by 564 · cited 1×
“This method of standardization was chosen in analogy with the tradition of reporting the level of denervation in the parkinsonian striatum relative to age-matched healthy controls in post-mortem studies (Fearnley and Lees, 1991; Kish et al., 1992; Hornykiewicz, 1998; Greffard et al., 2006).”
MethodGreffard, S., Verny, M., Bonnet, A.-M., Beinis, J.-Y., Gallinari, C., Meaume, S., Piette, F., Hauw, J.-J., & Duyckaerts, C. (2006) · Archives of Neurology · doi:10.1001/archneur.63.4.584 · Cited by 354 · cited 1×
“This method of standardization was chosen in analogy with the tradition of reporting the level of denervation in the parkinsonian striatum relative to age-matched healthy controls in post-mortem studies (Fearnley and Lees, 1991; Kish et al., 1992; Hornykiewicz, 1998; Greffard et al., 2006).”
MethodEffect of Mutant α-Synuclein on Dopamine Homeostasis in a New Human Mesencephalic Cell Line
Lotharius, J., Barg, S., Wiekop, P., Lundberg, C., Raymon, H. K., & Brundin, P. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m205518200 · Cited by 352 · cited 1×
“VMAT2, dopamine transporter, tyrosine hydroxylase and aromatic amino acid decarboxylase have been recognized as key players in Parkinson’s disease pathogenesis (Miller et al., 1997; Lotharius et al., 2002; Perez et al. 2002; Wersinger et al., 2003; Tehranian et al., 2006; Alerte et al., 2008; Liu et al., 2008; Afonso-…”
BackgroundKish, S. J., Shannak, K., Rajput, A., Deck, J. H. N., & Hornykiewicz, O. (1992) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1992.tb09766.x · Cited by 272 · cited 2×
“This method of standardization was chosen in analogy with the tradition of reporting the level of denervation in the parkinsonian striatum relative to age-matched healthy controls in post-mortem studies (Fearnley and Lees, 1991; Kish et al., 1992; Hornykiewicz, 1998; Greffard et al., 2006).”
MethodNandhagopal, R., Kuramoto, L., Schulzer, M., Mak, E., Cragg, J., Lee, C. S., McKenzie, J., McCormick, S., Samii, A., Troiano, A., et al. (2009) · Brain · doi:10.1093/brain/awp209 · Cited by 259 · cited 4×
“This confirms our previous finding that no selection bias was introduced through the missing data (Nandhagopal et al., 2009).”
BackgroundMethodResultInfluentialSelf-citationAge‐specific progression of nigrostriatal dysfunction in Parkinson's disease
de la Fuente‐Fernández, R., Schulzer, M., Kuramoto, L., Cragg, J., Ramachandiran, N., Au, W. L., Mak, E., McKenzie, J., McCormick, S., Sossi, V., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22284 · Cited by 222
Self-citationThe vesicular monoamine transporter is not regulated by dopaminergic drug treatments
Borght, T. V., Kilbourn, M., Desmond, T., Kuhl, D., & Frey, K. (1995) · European Journal of Pharmacology · doi:10.1016/0014-2999(95)00594-3 · Cited by 205
Immunochemical analysis of dopamine transporter protein in Parkinson's disease
Miller, G. W., Staley, J. K., Heilman, C. J., Perez, J. T., Mash, D. C., Rye, D. B., & Levey, A. I. (1997) · Annals of Neurology · doi:10.1002/ana.410410417 · Cited by 200 · cited 1×
“VMAT2, dopamine transporter, tyrosine hydroxylase and aromatic amino acid decarboxylase have been recognized as key players in Parkinson’s disease pathogenesis (Miller et al., 1997; Lotharius et al., 2002; Perez et al. 2002; Wersinger et al., 2003; Tehranian et al., 2006; Alerte et al., 2008; Liu et al., 2008; Afonso-…”
BackgroundHaycock, J. W., Becker, L., Ang, L., Furukawa, Y., Hornykiewicz, O., & Kish, S. J. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.02017.x · Cited by 194 · cited 1×
“To circumvent this problem, comparable standardized PET values were obtained as follows: (i) from the longitudinal PET data of healthy controls, the trajectory of normal ageing was obtained using linear mixed-effects models, allowing for missing data by means of the expectation maximization algorithm (Laird and Ware,…”
MethodWilson, J. M., & Kish, S. J. (1996) · The Journal of Neuroscience · doi:10.1523/jneurosci.16-10-03507.1996 · Cited by 127
Alpha‐synuclein inhibits aromatic amino acid decarboxylase activity in dopaminergic cells
Tehranian, R., Montoya, S. E., Van Laar, A. D., Hastings, T. G., & Perez, R. G. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04146.x · Cited by 114 · cited 1×
“VMAT2, dopamine transporter, tyrosine hydroxylase and aromatic amino acid decarboxylase have been recognized as key players in Parkinson’s disease pathogenesis (Miller et al., 1997; Lotharius et al., 2002; Perez et al. 2002; Wersinger et al., 2003; Tehranian et al., 2006; Alerte et al., 2008; Liu et al., 2008; Afonso-…”
BackgroundAlerte, T. N. M., Akinfolarin, A. A., Friedrich, E. E., Mader, S. A., Hong, C.-S., & Perez, R. G. (2008) · Neuroscience Letters · doi:10.1016/j.neulet.2008.02.014 · Cited by 98 · cited 1×
“VMAT2, dopamine transporter, tyrosine hydroxylase and aromatic amino acid decarboxylase have been recognized as key players in Parkinson’s disease pathogenesis (Miller et al., 1997; Lotharius et al., 2002; Perez et al. 2002; Wersinger et al., 2003; Tehranian et al., 2006; Alerte et al., 2008; Liu et al., 2008; Afonso-…”
BackgroundInvited Article: Functional imaging in Parkinson disease
Nandhagopal, R., McKeown, M. J., & Stoessl, A. J. (2008) · Neurology · doi:10.1212/01.wnl.0000310432.92489.90 · Cited by 77
Self-citationAfonso-Oramas, D., Cruz-Muros, I., de la Rosa, D. Á., Abreu, P., Giráldez, T., Castro-Hernández, J., Salas-Hernández, J., Lanciego, J. L., Rodríguez, M., & González-Hernández, T. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.09.002 · Cited by 70
Wersinger, C., Prou, D., Vernier, P., Niznik, H. B., & Sidhu, A. (2003) · Molecular and Cellular Neuroscience · doi:10.1016/s1044-7431(03)00124-6 · Cited by 64 · cited 1×
“VMAT2, dopamine transporter, tyrosine hydroxylase and aromatic amino acid decarboxylase have been recognized as key players in Parkinson’s disease pathogenesis (Miller et al., 1997; Lotharius et al., 2002; Perez et al. 2002; Wersinger et al., 2003; Tehranian et al., 2006; Alerte et al., 2008; Liu et al., 2008; Afonso-…”
BackgroundSilencing α-Synuclein Gene Expression Enhances Tyrosine Hydroxylase Activity in MN9D Cells
Liu, D., Jin, L., Wang, H., Zhao, H., Zhao, C., Duan, C., Lu, L., Wu, B., Yu, S., Chan, P., et al. (2008) · Neurochemical Research · doi:10.1007/s11064-008-9599-7 · Cited by 61 · cited 1×
“VMAT2, dopamine transporter, tyrosine hydroxylase and aromatic amino acid decarboxylase have been recognized as key players in Parkinson’s disease pathogenesis (Miller et al., 1997; Lotharius et al., 2002; Perez et al. 2002; Wersinger et al., 2003; Tehranian et al., 2006; Alerte et al., 2008; Liu et al., 2008; Afonso-…”
BackgroundVisualizing vesicular dopamine dynamics in Parkinson's disease
de la Fuente‐Fernández, R., Sossi, V., McCormick, S., Schulzer, M., Ruth, T. J., & Stoessl, A. J. (2009) · Synapse · doi:10.1002/syn.20653 · Cited by 56
Self-citationChapter 10 Aromatic L-amino acid decarboxylase modulation and Parkinson's disease
Neff, N. H., & Hadjiconstantinou, M. (1995) · Progress in brain research · doi:10.1016/s0079-6123(08)61206-6 · Cited by 40
Non-linear random effects model for multivariate responses with missing data
Marshall, G., de la Cruz, R., Barón, A. E., Rutledge, J. H., & Zerbe, G. O. (2005) · Statistics in Medicine · doi:10.1002/sim.2361 · Cited by 38 · cited 1×
“We modelled the longitudinal measurements of the standardized PET data in the Parkinson’s disease striatal subregions by non-linear multivariate regression analyses with random effects, allowing for missing data (Marshall et al., 2006).”
MethodThe dopamine transporter is differentially regulated after dopaminergic lesion
Afonso‐Oramas, D., Cruz‐Muros, I., Barroso‐Chinea, P., de la Rosa, D. Á., Castro‐Hernández, J., Salas-Hernández, J., Giráldez, T., & González‐Hernández, T. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.07.012 · Cited by 35
Cited by
Calabresi, P., Mechelli, A., Natale, G., Volpicelli-Daley, L., Di Lazzaro, G., & Ghiglieri, V. (2023) · Cell Death & Disease · doi:10.1038/s41419-023-05672-9 · Cited by 817
Blesa, J., Trigo-Damas, I., Dileone, M., del Rey, N. L.-G., Hernandez, L. F., & Obeso, J. A. (2017) · Experimental Neurology · doi:10.1016/j.expneurol.2017.10.002 · Cited by 256
Metadata
- Authors
- Nandhagopal, R., Kuramoto, L., Schulzer, M., Mak, E., Cragg, J., McKenzie, J., McCormick, S., Ruth, T. J., Sossi, V., de la Fuente-Fernandez, R., & Stoessl, A. J.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-11
- Volume
- 134
- Issue
- 11
- Pages
- 3290-3298
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2335662141
- Cited by
- 167
- References
- 31
- FWCI
- 5.67
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.